Deep 6 AI secured $17M in Series A Funding Round

Deep 6 AI, a California based provider of clinical trials acceleration software, recently secured $17 million in the Series A round of funding.

The round was led by the Point72 Ventures with the participation from strategic partners and GSR Ventures. As a part of this investment, Point72 Ventures partner Daniel Gwak will be going to join as the Deep 6 AI Board of Directors, said the announcement.

Founded in 2015, Deep 6 AI provides a suite of AI-driven tools designed to accelerate and optimize clinical trials design, recruitment, and management.

Executive Opinion

Point72 Ventures partner, Daniel Gwak, said, "We see clinical trials recruiting as a place where a data and AI-driven approach holds tremendous promise in accelerating life-saving research. Deep 6's track record in accelerating clinical trials through improved patient recruitment and trial design has resonated strongly with major healthcare providers and trial sponsors, who recognize Deep 6 as the clear leader in this field. We are excited to support them in scaling up to meet demand as more organizations recognize the need for and value from Clinical Trials Acceleration software."

Deep 6 AI CEO, Wout Brusselaers, said, "We are very excited to partner with Point72 Ventures to pursue our vision to build the leading global clinical trials acceleration software platform. Point72 Ventures’ emphasis on backing best-in-class category leaders validates Deep 6’s reputation as the product and technology leader in this new industry. Their investment will allow us to rapidly scale up to meet the high demand for our software, as health systems recognize the significant opportunity from leveraging AI to turn their research efforts into a growth and profit centre."

More on Deep 6 AI Tools 

The company, as of now, plans to use the funds to expand its business reach among the healthcare provider, pharma companies and contract research organizations and enhance its suite of Artificial Intelligence native software products.
Deep 6 AI tools parse clinical trial qualification criteria and match against repositories of structured and unstructured patient health data at participating trial sites. This helps in reducing the delays that potentially cost trial sponsors millions of dollars in lost revenue. The tool also helps in finding qualified patients before they invest in activating trial sites and recruiting patients.

The company solution uses the AI to parse clinical trial qualification criteria and match against the repositories of structured and unstructured patient health data at participating trial sites.

The customers of Deep 6 AI include the Texas Medical Center and Cedars Sinai Medical Center, notes the announcement.